Vaccines are here, capitalizing on capital with IPOs, and Gilead targets Hepatitis D

Everlywell expands at-home testing, Bayer and Atara strike deal, and Moderna heads to the FDA.

We take a thanksgiving break from the news cycle to bring you a special interview with a COVID survivor and healthcare worker, Trenton Barrick. He shares an inside perspective on the healthcare industry as well as his personal experience being hospitalized with COVID19.

Pfizer submits to the FDA, how mRNA vaccines work, and Novartis drops a billion, but really only $50 million

COVID19 vaccine news, an app to stop nightmares, Agios targets Sickle Cell disease, and Silverback files to go public.

Aducanumab skeptics, Novo Nordisk and Merck make acquisitions, but first a market update.

Syneos Health acquires Synteract, Apellis strikes a billion-dollar deal, and clinical trial patient enrollment, but first a market update.

Site-less with vision, IQVIA back on track, 36%, convalescent plasma, and Remdesivir approved.

Failures in sickle-cell therapy, CRO mergers in Asia, Praxis IPO, and wasp venom.

Nobel Prizes, clinical trials for tinnitus, Takeda’s billion-dollar deal, and the White House keeps science political.

Bristol Myers strikes a $13 billion deal, presidential experiments, the NIH funds under-represented testing, and Sophia Genetics raises $110 million.

Another Alzheimer’s failure, COVID19 updates, two stories in the supplements space, and Taysha goes public.

Finch does probiotics the expensive way, lipid nanoparticles, a followup on transparency, and LAVA gains immuno-therapy support.

Vaccines and shark statistics, are noses the ultimate pipedream, and eye drops to replace eye-glasses.

Roche earns FDA approval for a combined flu/COVID diagnostic, I-Mab signs with Abbvie for $2 billion, PPD partners to treat lupus, and BioNTech/Pfizer add more COVID candidates while Moderna adds bad press.

Johnson & Johnson acquires Momenta, the White House and FDA disagree, and the emergence of decentralized clinical trial management.

Samsung Biologics builds big, Modern (again), microparticles for timed-release chemotherapy, and Qiagen says ‘no’ to acquisitions.

Biogen and Denali partner for Parkinson’s, the US pushes American-based drug manufacturing, and the secret to Parasitic Sexual Partners uncovered.

We review a few of the big winners from operation warp speed, Merck continues to be quietly successful, and a new CAR T treatment, Tecartus, gets FDA approval.

Abbott and the FDA develop digital healthcare, Roche gives us some market insight, and we look at Encoded’s approach to gene therapy.